Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29118006 | 1.00 | ROCK2 (0.50) | ROCK2KDM4EHSD17B10HPGDNPSR1 | |
| SCHEMBL27029902 | 1.00 | ROCK2 (0.50) | ROCK2KDM4EHSD17B10HPGDNPSR1 | |
| SCHEMBL29118052 | 1.00 | ROCK2 (0.50) | ROCK2KDM4EHSD17B10HPGDNPSR1 | |
| SCHEMBL29118005 | 1.00 | ROCK2 (0.50) | ROCK2KDM4EHSD17B10HPGDNPSR1 | |
| SCHEMBL29117985 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL21963537 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL1670922 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL15796256 | 0.87 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL29367258 | 0.87 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL29614755 | 0.81 | HCRTR1 (0.43) | KDM4EHSD17B10HPGDNPSR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4310089-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-4310089-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981670-A | Polycyclic compound containing nitrogen heterocycle, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022194122-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HCRTR1, HCRTR2, CCKBR | ROCK2 3619/4885KDM4E 3486/4885HSD17B10 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.